Skip to Content
Merck
  • Adriamycin-induced nephropathy in rats: functional and cellular effects characterized by MRI.

Adriamycin-induced nephropathy in rats: functional and cellular effects characterized by MRI.

Journal of magnetic resonance imaging : JMRI (2014-03-07)
Christine Egger, Catherine Cannet, Christelle Gérard, Corinne Debon, Nadine Stohler, Andrew Dunbar, Bruno Tigani, Jianping Li, Nicolau Beckmann
ABSTRACT

To assess with magnetic resonance imaging (MRI) adriamycin-induced nephropathy in living rats, an established model for proteinuric renal disease was used. Functional information of contrast agent clearance was obtained with dynamic contrast-enhanced (DCE) imaging following intravenous Gd-DOTA administration. Perfusion data were obtained with a bolus tracking technique comprising intravenous injection of superparamagnetic iron oxide (SPIO) nanoparticles. Cellular information was derived from anatomical images acquired 24 hours after SPIO. Treatment with the transforming growth factor-β123 (TGF-β1,2,3 ) antibody, 1D11, started 1 week after adriamycin. Histology was performed at week 6 post-adriamycin. Tracer washout rates derived by DCE-MRI decreased by 65.5% with respect to baseline at week 6 post-adriamycin. The impaired kidney function agreed with glomerulopathy, nephropathy and fibrosis revealed histologically (picrosirius collagen staining in adriamycin-treated rats increased by 125.8% [P = 0.005] with respect to controls). Perfusion was reduced by 16.1%. Images acquired 24 hours after SPIO presented contrast changes that correlated inversely with the histologically determined iron content (R = -0.74, P = 2.6 × 10(-4) ). In adriamycin-challenged animals, iron was found in macrophages and in sclerotic tubuli, only in areas where macrophages were present. Treatment with 1D11 did not improve the adriamycin-induced renal injury. MRI provides longitudinal functional and cellular (macrophage infiltration) information that correlates with nephropathy development in adriamycin-challenged rats.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrogen chloride solution, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
Sodium hydroxide solution, 4 M
Sigma-Aldrich
Sodium hydroxide solution, 7 M
Sigma-Aldrich
Sodium hydroxide solution, 1 M
Sigma-Aldrich
Sodium hydroxide solution, 6 M
Sigma-Aldrich
Hydrochloric acid solution, 0.5 M
Sigma-Aldrich
Hydrochloric acid solution, 12 M
Sigma-Aldrich
Hydrochloric acid solution, 2 M
Sigma-Aldrich
Hydrochloric acid solution, 1 M
Sigma-Aldrich
Hydrochloric acid solution, 6 M
Sigma-Aldrich
Sodium hydroxide solution, 0.01 M
Sigma-Aldrich
Hydrogen chloride – ethanol solution, 0.1 M in ethanol
Sigma-Aldrich
Sodium hydroxide solution, 0.05 M
Sigma-Aldrich
Hydrochloric acid solution, 0.2 M
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium hydroxide solution, 0.2 M
Supelco
Sodium hydroxide concentrate, 0.1 M NaOH in water (0.1N), Eluent concentrate for IC
Sigma-Aldrich
3-Ethyl-2,4-pentanedione, mixture of tautomers, 98%
Sigma-Aldrich
Sodium hydroxide solution, BioUltra, for molecular biology, 10 M in H2O
Supelco
Hydrogen chloride – 2-propanol solution, ~1.25 M HCl (T), for GC derivatization, LiChropur
Supelco
Hydrogen chloride – ethanol solution, ~1.25 M HCl, for GC derivatization, LiChropur
Supelco
Hydrogen chloride – methanol solution, ~1.25 m HCl (T), for GC derivatization, LiChropur
Sigma-Aldrich
Sodium hydroxide, BioUltra, for luminescence, ≥98.0% (T), pellets
Supelco
Sodium hydroxide solution, 49-51% in water, eluent for IC
Sigma-Aldrich
Hydrochloric acid solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Sigma-Aldrich
Hydrochloric acid, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
Sodium hydroxide, ultra dry, powder or crystals, 99.99% trace metals basis
USP
Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Hydrochloric acid, SAJ first grade, 35.0-37.0%